Stampa

W06 Ricerca farmaco

A phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer
2015-003447-19
ARIAD Pharmaceuticals Inc. un’azienda interamente controllata da Takeda Pharmaceutical Company Limited
AP26113
28-11-2016
29-11-2016
8264.00
2529.00
10793.00

Pincipal investigators

Oncologia di Ravenna
Federico Cappuzzo